Aclaris Therapeutics (ACRS) Capital Expenditures (2014 - 2026)

Aclaris Therapeutics' Capital Expenditures history runs 13 years deep, the most recent figure standing at $13000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 69.77% year-over-year to $13000.0; the TTM figure through Mar 2026 stood at -$9000.0 (down 131.03% YoY), while the FY2025 annual figure was $21000.0, down 82.64% from the prior year.
• Capital Expenditures was $13000.0 for Q1 2026 at Aclaris Therapeutics, up from -$66000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $933000.0 in Q4 2023 to a low of -$159000.0 in Q2 2023.
• Historically, Capital Expenditures has averaged $137933.3 across 5 years, with a median of $21000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 1617.14% in 2022, then sank 307.69% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $601000.0 in 2022, then surged by 55.24% to $933000.0 in 2023, then sank by 101.5% to -$14000.0 in 2024, then tumbled by 371.43% to -$66000.0 in 2025, then jumped by 119.7% to $13000.0 in 2026.
• The last three Capital Expenditures figures came in at $13000.0 (Q1 2026), -$66000.0 (Q4 2025), and $23000.0 (Q3 2025), per Business Quant data.